Clinical Trial Update: Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating FluGlucoScan using 18F-fluorodeoxyglucose imaging in patients with known or suspected soft tissue sarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• FluGlucoScan (fluorodeoxyglucose)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Sarcoma | Phase 2 | Status: TERMINATED